Year Founded
2004
Ownership
Private
Employees
~50
Therapeutic Areas
Men's HealthEndocrinology
Stage
Commercial
Modalities
Small molecule

Diurnal General Information

Two commercial products: Alkindi for pediatric adrenal insufficiency (approved in EU/US) and Efmody for congenital adrenal hyperplasia (approved in EU/UK). Ongoing clinical trials include CONnECT study for Efmody expansion and CHAMPAIN study for adult AI indication.

Contact Information

Website
Primary Industry
Pharma
Corporate Office
Cardiff, Wales
United Kingdom

Drug Pipeline

hydrocortisone
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Diurnal's pipeline data

Book a demo

Key Partnerships

Neurocrine Biosciences (acquirer)

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Diurnal Funding

Deal TypeDateAmountStatusStage
Later Stage VCJan 6, 2016$44.6MCompletedCommercial
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Diurnal's complete valuation and funding history, request access »

Diurnal Licensing Deals

AssetLicenseeDateTherapeutic Area
alkindi sprinkleEton PharmaceuticalsMar 26, 2020Endocrinology
alkindi sprinkleEton PharmaceuticalsN/ARare genetic
You're viewing 2 of 2 licensing deals. Get the full list »